Special Issue

Targeting Metabolic Vulnerabilities in Cancer

Message from the Guest Editors

Metabolism has recently emerged as a new potential therapeutic target in oncology. Altered metabolic pathways are crucial for tumor development and growth, including increased glucose uptake, glycolytic rates, OXPHOS activities and lipid production. In the last years. these perturbations have been exploited in order to increase the therapeutic response. Different pharmacological strategies targeting metabolic networks, as well as the use of particular diet regimens combined with treatment, have been developed and have shown promising efficacy in both preclinical and clinical studies. This Special Issue aims to increase the knowledge of the different therapeutic approaches that target cancer metabolic perturbations in order to increase the response to therapy and avoid the development of resistance. The submission of manuscripts approaching innovative therapeutic strategies targeting cancer metabolism, as well as the presentation of new preclinical models useful for this kind of research, is encouraged. Translational research studies and systematic and perspective reviews are also welcome.

Guest Editors

Dr. Francesca Ricci
Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Mialn, Italy
Dr. Laura Brunelli

Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

Deadline for manuscript submissions

closed (30 July 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



mdpi.com/si/119628

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

